Skip to main content
DYN logo

Dyne Therapeutics, Inc. (DYN) Stock: Price, Forecast & Analyst Target

Dyne Therapeutics, Inc. (DYN) — MoonshotScore 46/100 (Fair band), calculated Nov 18, 2026. Price $16.03 (+1.01%), as of the Nov 19, 2026 trading session; market cap $3.00B.

Educational signal · not a buy or sell recommendation · How to read this

$16.03 +$0.16 (+1.01%) Market Cap $3.00B

Dyne Therapeutics, Inc. · DYN · NASDAQ

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for genetically driven muscle diseases. Their FORCE platform aims to deliver disease-modifying treatments for conditions like myotonic dystrophy and Duchenne muscular dystrophy.

Price as of Nov 19, 2026

Key Statistics

46 of 100

MoonshotScore v2 · Dyne Therapeutics (DYN)

Fair
Business Quality Thin (35)
Financial Safety Okay (43)
Valuation Full (40)
Growth Durability Shrinking (10)
Momentum Quiet (47)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, stalling growth and a full valuation, though the balance sheet is only middling. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.

  • quarterly revenue $0 (Q3 FY2026, quarter ended Sep 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z 3.29 · Piotroski F 1

Holding back: soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DYN (57 recorded, newest six shown)
RecordedScoreBand
47Fair
48Fair
46Fair
46Fair
46Fair
46Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$16.03
Change on the day+1.01%
52-week range$14.00 – $27.31
Market capitalisation$3.00B—
Shares traded on the day2.44M

Price & events

Other perspectives

Council score for Dyne Therapeutics (DYN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Neutral
Growth Durability Negative
Momentum Neutral

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Moderate
ROE Negative
Gross Margin Negative

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Dyne Therapeutics (DYN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Dyne Therapeutics, Inc. (DYN) is listed on NASDAQ. It employs 289 people and is led by John G. Cox. In Q3 FY2026 it reported revenue of $0 and net income of -$194M. The market values it at $3.00B.

2 · Latest results

What do the latest results show for Dyne Therapeutics (DYN)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$0-$194M-$1.06 (diluted)
Q2 FY2026$0-$179M-$1.08 (diluted)
Q1 FY2026$0-$121M-$0.73 (diluted)
Q4 FY2025$0-$112M-$0.87 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Dyne Therapeutics (DYN)?

Short answer

What is holding it back is soft growth. The distress and quality screens read Altman Z 3.29 · Piotroski F 1. Trailing ratios: ROE -74.6% · ROA -36.9% · current ratio 12.99.

Data-derived red flags

  • Negative return on equity (-74.6%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Dyne Therapeutics (DYN)?

Short answer · as of

Current published price targets run low $26.00 · high $50.00 · consensus $36.88 · median $36.50 against a quoted price of $16.03 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Dyne Therapeutics compare with its peers?

Short answer

Dyne Therapeutics's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.26 Nov 19, 2026$2.97B95 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Veracyte, Inc. (VCYT) Same industry, near in market value$25.57 Nov 18, 2026$2.06B89 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.41 Nov 19, 2026$3.42B72 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.20 Nov 19, 2026$3.37B66 5-pillar Nov 18, 2026
SELLAS Life Sciences Group, Inc. (SLS) Same industry, near in market value$14.86 Nov 19, 2026$3.03B63 5-pillar Nov 18, 2026
Tango Therapeutics, Inc. (TNGX) Same industry, near in market value$21.89 Nov 18, 2026$3.71B62 5-pillar Nov 18, 2026
MBX Biosciences (MBX) Same industry, near in market value$53.41 Nov 19, 2026$2.65B61 5-pillar Nov 18, 2026
Dyne Therapeutics (DYN) — this page$16.03$3.00B46
Celcuity Inc. (CELC) Named competitor$56.31 Nov 19, 2026$2.76B45 5-pillar Nov 18, 2026
CG Oncology Inc (CGON) Named competitor$81.90 Nov 19, 2026$7.32B26 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$26.00 – $50.00
Consensus target
$36.88
Median target
$36.50

Consensus record · Captured .

Measured against a quoted price of $16.03 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 20, 2026

Transactions
65
Identified insiders
12
Purchases
4
Sales
51
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DYN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DYN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Dyne Therapeutics (DYN)?

Read these with our analysis →

What Investors Ask About Dyne Therapeutics (DYN)

These answers are editorial: 1 of these 9 answers is drawn from the DYN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for DYN?

DYN carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for genetically driven muscle diseases.

Is DYN a good stock to buy?

Stock Expert AI does not rate DYN buy, sell or hold. Dyne Therapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DYN stock price today?

The last price recorded for Dyne Therapeutics, Inc. (DYN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the DYN price target?

The analyst consensus price target for Dyne Therapeutics, Inc. (DYN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What do analysts say about DYN stock?

Analyst consensus on DYN stock reflects a cautiously optimistic outlook, driven by the potential of its FORCE platform and pipeline programs. Key valuation metrics include discounted cash flow analysis based on projected revenue from its lead programs.

What are the key factors to evaluate for DYN?

Dyne Therapeutics, Inc. (DYN) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Dyne Therapeutics focuses on genetically driven muscle diseases, a niche market with significant unmet medical needs. Not financial advice.

How frequently does DYN data refresh on this page?

DYN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DYN's recent stock price performance?

Dyne Therapeutics, Inc. (DYN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary FORCE platform for targeted drug delivery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DYN overvalued or undervalued right now?

Dyne Therapeutics, Inc. (DYN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 12 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.